Next Article in Journal
Salinity-Induced Variation in Biochemical Markers Provides Insight into the Mechanisms of Salt Tolerance in Common (Phaseolus vulgaris) and Runner (P. coccineus) Beans
Next Article in Special Issue
Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer
Previous Article in Journal
Recent Advances in Antimicrobial Polymers: A Mini-Review
Previous Article in Special Issue
Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2016, 17(9), 1580;

Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back

Axencia Galega de Coñecemento en Saúde (ACIS), SERGAS, Avda, Fernando de Casa Novoa, Santiago de Compostela 15707, Spain
London Regional Cancer Program, London Health Sciences Centre, London, ON N6A 4L6, Canada
Translational Medical Oncology/Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Trav. Choupana s/n, Santiago de Compostela 15706, Spain
Authors to whom correspondence should be addressed.
Academic Editor: Dario Marchetti
Received: 2 July 2016 / Revised: 5 September 2016 / Accepted: 9 September 2016 / Published: 20 September 2016
(This article belongs to the Special Issue Circulating Tumor Cells)
Full-Text   |   PDF [549 KB, uploaded 20 September 2016]   |  


Prostate cancer is the most common cancer in men worldwide. To improve future drug development and patient management, surrogate biomarkers associated with relevant outcomes are required. Circulating tumour cells (CTCs) are tumour cells that can enter the circulatory system, and are principally responsible for the development of metastasis at distant sites. In recent years, interest in detecting CTCs as a surrogate biomarker has ghiiukjrown. Clinical studies have revealed that high levels of CTCs in the blood correlate with disease progression in patients with prostate cancer; however, their predictive value for monitoring therapeutic response is less clear. Despite the important progress in CTC clinical development, there are critical requirements for the implementation of their analysis as a routine oncology tool. The goal of the present review is to provide an update on the advances in the clinical validation of CTCs as a surrogate biomarker and to discuss the principal obstacles and main challenges to their inclusion in clinical practice. View Full-Text
Keywords: prostate cancer; circulating tumour cells; tumour markers; precision oncology prostate cancer; circulating tumour cells; tumour markers; precision oncology

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

León-Mateos, L.; Vieito, M.; Anido, U.; López López, R.; Muinelo Romay, L. Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back. Int. J. Mol. Sci. 2016, 17, 1580.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top